Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Hutzen

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Molecular Therapy Oncolytics|December 4, 2018
Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune MicroenvironmentNicholas L Denton, Chun-Yu Chen, Brian Hutzen, et al.
Molecular Therapy Oncolytics|October 6, 2015
Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in childrenTimothy P Cripe, Chun-Yu Chen, Nicholas L Denton, et al.
Molecular Therapy Oncolytics|October 6, 2015
Pediatric cancer gone viral. Part II: potential clinical application of oncolytic herpes simplex virus-1 in childrenGregory K Friedman, Elizabeth A Beierle, George Yancey Gillespie, et al.
Molecular Therapy. Methods & Clinical Development|August 13, 2025
Development of VNX-101, an adeno-associated virus with less immunogenicity and efficient long-term expression of a CD19 T cell engagerMark A Currier, Allen Reha, Brian Hutzen, et al.
Science Advances|July 20, 2022
Leveraging gene therapy to achieve long-term continuous or controllable expression of biotherapeuticsTimothy P Cripe, Brian Hutzen, Mark A Currier, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Molecular Therapy Oncolytics|December 4, 2018
Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune MicroenvironmentNicholas L Denton, Chun-Yu Chen, Brian Hutzen, et al.
Molecular Therapy Oncolytics|October 6, 2015
Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in childrenTimothy P Cripe, Chun-Yu Chen, Nicholas L Denton, et al.
Molecular Therapy Oncolytics|October 6, 2015
Pediatric cancer gone viral. Part II: potential clinical application of oncolytic herpes simplex virus-1 in childrenGregory K Friedman, Elizabeth A Beierle, George Yancey Gillespie, et al.
Molecular Therapy. Methods & Clinical Development|August 13, 2025
Development of VNX-101, an adeno-associated virus with less immunogenicity and efficient long-term expression of a CD19 T cell engagerMark A Currier, Allen Reha, Brian Hutzen, et al.
Science Advances|July 20, 2022
Leveraging gene therapy to achieve long-term continuous or controllable expression of biotherapeuticsTimothy P Cripe, Brian Hutzen, Mark A Currier, et al.
Pageof 3